Suzetrigine Drug Asset Due Diligence Report 2026

This Suzetrigine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Suzetrigine can convert its Small molecule drug profile and Nav1.8 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Suzetrigine (query alias: suzetrigine)
Modality / target	Small molecule drug; Nav1.8; Nav1.8 blockers
Highest global status	Approved
Originator	Vertex Pharmaceuticals, Inc.
Active developers	Vertex Pharmaceuticals, Inc., Vertex Pharmaceuticals (Canada), Inc.

The MCP disease footprint includes Acute Pain, Analgesia, Diabetic peripheral neuropathic pain. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07600697	Phase 4	Not yet recruiting	120	Pain intensity (0-10 NRS) at 48 hours postoperatively
NCT07672015	Phase 4	Recruiting	100	Total Opioid Consumption Over 14 Days Postoperatively
NCT07624526	Phase 4	Not yet recruiting	75	Mean pain intensity score on the Numeric Rating Scale (NRS)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Protocol for a prospective single-arm feasibility study of suzetrigine for postoperative pain management in outpatient facial plastic surgery

Phase 3; n=60; evaluation: Positive. Reported fields: AE = While suzetrigine has demonstrated efficacy in phase III trials of acute postoperative pain, its use in facial plastic surgery has not been studied.

The Clinical Application of Suzetrigine

Phase 2/3; n=475; evaluation: Positive. Reported fields: Pain Relief(48 hour): P-Value = < 0.05; Pain Relief(48 hour): P-Value = < 0.05

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

Phase 3; n=1118; evaluation: not stated. Reported fields: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo(Least Squares Mean) = 70.1 units on a scale (Standard Error, 6.1); Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo(Least Squares Mean): P-Value = <0.0001; Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo(Least Squares Mean): P-Value = <0.0001

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Suzetrigine addresses Acute Pain, Analgesia, Diabetic peripheral neuropathic pain. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Nav1.8 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-04-13	Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain	Phase 2	US$30.0M upfront; US$715.0M milestones
2025-05-27	Lilly Follows Vertex Into Non-Opioid Pain With up to $1B SiteOne Buy	Phase 1	US$1,000.0M stated total
2023-11-14	费米子独家授权健康元镇痛新药FZ008-145大中华区权益，实现AI制药商业闭环	IND Application	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain”. The milestone feed surfaced a patent-application signal described as “Substituted tetrahydrofurans as nav1.8 inhibitors”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO